Home > Haematology > EHA 2021 > Leukaemia > Sabatolimab achieved durable responses in patients with high-risk MDS and AML

Sabatolimab achieved durable responses in patients with high-risk MDS and AML

Presented By
Prof. Andrew Wei, Alfred Hospital and Monash University, Australia
Conference
EHA 2021
Sabatolimab plus hypomethylating agents (HMA) showed durable responses in a phase 1b study in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) with poor-outcome cytogenetic risk profiles. Treatment was well tolerated. Novel therapies with durable efficacy and favourable safety profiles represent an unmet medical need in high-risk and very high-risk MDS (HR/VeryHR MDS) and AML. TIM-3 is an inhibitory receptor expressed on immune and leukaemic cells but not on normal haematopoetic stem cells. Sabatolimab is a novel immuno-myeloid therapy targeting TIM-3. Prof. Andrew Wei (Alfred Hospital and Monash University, Australia) presented updated results of a multi-arm, open-label, phase 1b study (NCT03066648) [1]. The study enrolled patients with HR/VeryHR MDS or newly diagnosed AML unfit for chemo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on